stockrow
Tuesday 3 November 2026
Export OSCR’s income statement to Excel — free account
Oscar Health, Inc.
OSCR Healthcare Healthcare Plans
Oscar Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $11.7 billion, up 27.5% from fiscal 2024.
- Revenue
- +70.4%
- EPS
- +234.8%
- Free cash flow
- +316.3%
- Total debt
- +43.9%
Quarter to June 2026, against a year earlier
31.00
0.63
+2.07%
Follow OSCR
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
16.68 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.56 | 0.26 | 0.32 | 0.43 | |
P/FCF ratio |
1.97 | 1.22 | 3.56 | 6.67 | |
P/Operating CF |
4.12 | 1.31 | 5.61 | (5.09) | |
P/B ratio |
4.19 | 2.05 | 3.84 | 4.78 | |
Price to Tangible BV |
4.19 | 2.05 | 3.84 | 4.78 | |
EV/Sales |
0.32 | (0.07) | 0.12 | 0.31 | |
EV/EBITDA |
7.87 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
1.13 | (0.34) | 1.30 | 4.48 | |
EV/FCF |
1.14 | (0.34) | 1.35 | 4.68 | |
Quick Ratio |
0.57 | 0.83 | 0.72 | 0.69 | |
Current Ratio |
0.57 | 0.83 | 0.72 | 0.69 | |
Net Debt/EBITDA |
(9.40) | (6.20) | 7.07 | 11.34 | |
Debt/Assets |
3.84% | 4.64% | 6.80% | 11.94% | |
Debt/Equity |
0.21 | 0.26 | 0.44 | 0.67 | |
Asset Turnover |
1.74 | 1.76 | 2.10 | 2.21 | |
Operating CF/Net income |
5.78 | 3.86 | (1.91) | 7.02 | |
Capex/Depreciation |
11.43 | (9.20) | (4.51) | (30.22) | |
Interest Coverage |
82.53 | 130.80 | 304.24 | (18.85) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
14.16% | 15.20% | 18.22% | 17.47% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.42% | 0.34% | 0.64% | 0.69% | |
Graham Net Nets |
(0.50) | (0.55) | (0.52) | (0.41) | |
Graham Number |
16.18 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
6.00% | (3.31%) | (10.86%) | (4.97%) | |
Free Cash Flow Yield |
50.82% | 81.84% | 28.07% | 14.99% | |
Revenue per Share |
16.15 | 15.59 | 10.69 | 11.52 | |
Operating CF per Share |
6.92 | 8.78 | 2.56 | (3.72) | |
Capex per Share |
(0.04) | (0.03) | (0.03) | (0.03) | |
Free Cash Flow per Share |
6.88 | 8.75 | 2.53 | (3.76) | |
Cash per Share |
13.49 | 16.11 | 10.57 | 8.29 | |
Shareholders Equity per Share |
6.80 | 5.59 | 3.74 | 3.96 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
6.80 | 5.59 | 3.74 | 3.96 | |
Free Cash Flow |
2,080.58 | 2,610.19 | 662.84 | (973.66) | |
Working Capital |
(3,689.03) | (1,211.51) | (1,323.77) | (1,212.76) | |
Capital Expenditures |
(11.76) | (8.79) | (9.06) | (9.01) | |
Net Current Asset Value |
(4,338.63) | (1,865.75) | (1,972.06) | (2,031.94) | |
EV/EBIT |
7.90 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
13.69 | 322.51 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
655.18 | 763.80 | 489.57 | 451.11 | |
Average Payables |
6,659.03 | 5,523.01 | 4,042.61 | 3,394.18 | |
Average Assets |
8,805.44 | 7,566.71 | 5,582.95 | 5,114.45 | |
Average Common Equity |
1,608.26 | 1,501.58 | 998.58 | 1,096.17 |
Columns are period end dates